Antibiotics

Dhineli Perera chats with clinical pharmacologist and fellow podcast host David Liew about Australia's top 10 drugs over the last 2 years. David explains the relationship between the PBAC and the PBS and the different ways the top 10 drugs are presented, and offers some insights into why particular drugs are on the lists.
Read the full articles for 2021-22 and 2022-23 in Australian Prescriber.

In this thought-provoking episode of the 'Buckets of Change' podcast, host Nick Goblirsch delves into the profound topic of the value we assign to our time and the choices we make daily. Kicking off the New Year of 2024, Nick openly shares his reflections on personal growth, career transitions, and the importance of spending our finite time on what truly matters.

In particular, Nick revisits his past choices, evaluating the worth of the time he allocated to his work versus family and recognizing missed opportunities. He encourages listeners to ponder the fulfillment they derive from their careers and to reassess whether their time is gratifying not only in financial terms but also in personal happiness and presence with loved ones. Generating an atmosphere of contemplation, this episode is a compelling nudge to contemplate the worth we place on different aspects of our lives.

Key Takeaways:

• Time is a finite resource and how we choose to spend it should bring fulfillment, joy, and presence with the important people in our lives.
• Reflecting on past career choices can provide insights into the value we may (or may not) have placed on our time and the potential need for change.
• It's important to reevaluate the company we keep, as spending time with negative or unproductive individuals can affect our own outlook and life choices.
• Assigning a dollar amount to time in a professional setting, as Nick does with painting estimates, requires considering the value provided to the client beyond just financial cost.
• The 'Buckets of Change' assessment is mentioned as a resource for listeners in similar situations, aiming to help them make more conscious and fulfilling career choices.

Are there signs that change me be necessary in your life, especially in your current career path? TAKE THIS FREE 5 Minute Buckets of Change Assessment to see if those signs for change are right in front of you.  CLICK HERE to take your Buckets of Change Assessment

FOLLOW me on the SOCIALS:

On your Phone - Instagram & Facebook @bucketsofchange and on TikTok @nickgoblirsch

On your Desktop - Instagram https://www.instagram.com/bucketsofchange/ and coming soon to Facebook 

EMAIL the SHOW: nick@bucketsofchange.com

Music on this composed and performed by Bjurman - "Hiccup (Instrumental)". So grateful for your talented tunes. 

You are host to the deadliest viruses in the world. Researcher Kristin Bates offers insight into bacteriophages, how they are such effective killers of bacteria, why they could be so effective in field-forward settings, and how they could one day serve as an alternative or complementary treatment to antibiotics.

A busy journal club in which Justin and I discuss 13 papers that might help you on your next shift in the Emergency department.

Welcome to What’s it Worth! Join your host Dr. Diana Langworthy, & co-host Marina Fahim, as we ATTACK the critique of a non-inferiotiy study design. Our expert guest for this episode is Dr. Betsy Hirsch, Assoiate Professor and Infectious Diseases Translational Researcher. We're discussing a trial that compared a new beta-lactam antibiotic, sulbactam/durlobactam, with colistin for the treatment of Acinetobacter baumannii infections. Join us as we discuss the key points of a non-inferiority trial design as we determine what this article is worth!

Key Points

1. Non-inferiority (NI) trials are indicated when there are other effective treatment options or where it would unethical to expose a group to placebo
2. Acinetobacter baumannii-calcoaceticus (ABC) is seen in hospital acquired infections and presents a clinical challenge to practitioners given its increasing resistance patterns
3. NI margins are important components to critique when reviewing these trials to determine clinical implications and whether the margin is clinically justifiable 
4. How inferior is considered "non-inferior"? --> Tune in to find out!

References

1. [EPISODE TRIAL] Kaye KS, Shorr AF, Wunderink RG, et al.  Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex:  a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).  Lanced Infect Dis 2023; Sep;23(9):1072-1084.  doi: 10.1016/S1473-3099(23)00184-6.
2. Tamma PD, Aitken SL, Bonomo RA, et al.  Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. CID 2023, ciad428,  https://doi.org/10.1093/cid/ciad428
3.  Product Information: XACDURO(R) intravenous kit, sulbactam, durlobactam intravenous kit. La Jolla Pharmaceutical Company (per manufacturer), Waltham, MA, 2023.
4. Tsuji BT, Pogue JM, Zavascki AP, et al.  International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-Infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP).  Pharmacotherapy 2019;39(1):10-39.  https://accpjournals.onlinelibrary.wiley.com/doi/full/10.1002/phar.2209

Contact Information

Podcast email: whatsitworthpodcast@gmail.com

Host Information

Dr. Diana R. Langworthy, PharmD, BCPS

Clinical Associate Professor, University of Minnesota College of Pharmacy

Clinical Pharmacist - Inpatient Internal Medicine, M Health Fairview East Bank Hospital

Co-Host Information

Marina Fahim, Student Pharmacist, Class of 2024  University of Minnesota

Guest Host Information

Dr. Betsy Hirsch, PharmD, FCCP, FIDSA

Associate Professor, Experimental and Clinical Pharmacology

Infectious Diseases Translational Researcher

University of Minnesota College of Pharmacy

After working in the government sector for nearly 20 years, Ricardo Wilkins discovered there was more to see, do, and share in life. Learning about the vital role of Redox Signaling led him on his path to entrepreneurship, personal development, and guiding others while following his other inspiration, travel. His vision is for everyone to Be Healthy, Be Inspired, and Live Free.

In this episode of Navigating Cancer TOGETHER, Ricardo shares his journey of discovering the importance of redox signaling and the idea that paying attention to our health and making positive changes can lead to a better quality of life.

✨A few highlights from the show:  

[00:06:40] Redox signaling. 

[00:07:43] The orchestra of health. 

[00:14:45] The future of redox signaling.  

[00:24:10] Living on the road. 

Resources:  

Redox Medicine Society - https://www.redox-medicine.com/ 

The Amazing Way Redox Signaling Stops Mutated Cell Growth and Spread Part II - https://www.linkedin.com/pulse/amazing-way-redox-signaling-stops-mutated-cell-growth-ricardo-wilkins/?trackingId=eeZxHRJPRAOf0BC5dSg7CA%3D%3D 

📰 Blog:  https://www.ontheotherside.life/post/understanding-redox-signaling 

Read the transcript for this episode. https://drive.google.com/file/d/1rkjIlUlUkkOfiRjXevQ6J-7eDaaBV9Ob/view?usp=drive_link 

Connect and learn more about Ricardo:

Website: www.lifeandredox.com 

LinkedIn - https://www.linkedin.com/in/rwilkins23 

Book: Life's BioHack - https://www.amazon.com/Lifes-Biohack-Environment-Threatening-Extraordinary/dp/B0BRM2N2HH 

🦄About Me:

In 2011, I was diagnosed with Hodgkin's Lymphoma, out of the blue. I did not have any prior health concerns or issues. Fast forward, the dreaded cancer diagnosis opened my eyes, introduced me to my purpose, and led me to where I am today. 

As a Cancer Doula, I use my 12 years of experience with cancer to support and guide others diagnosed with cancer. Many people are not familiar with what a cancer doula is. Think of me as your personal guide and patient advocate. Schedule a 30-minute Meet and Greet call to confidentially share the challenges you are facing and learn more about how I can support you. https://bit.ly/OTOSDiscovery 

Learn more about On the Other Side at https://www.ontheotherside.life/. Connect with me on LinkedIn (https://www.linkedin.com/in/talayadendy/), or sign up for my bi-weekly newsletter  (https://bit.ly/OTOSNewsletter) to get valuable information and resources that can help you navigate cancer. 

🙏🏼Thanks for joining us for this episode of Navigating Cancer TOGETHER!

💜If you found this podcast helpful, why not spread the love and share it with others? Together, we can help more people benefit from this valuable resource!

Disclaimer: The information on this podcast is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation, or care from your physician or other qualified health care provider.      

In the second part of this podcast, Jonathan and Mark de Boer, current president of the Dutch Working Party on Antibiotic Policy (SWAB) focus on the ‘marathon’ of antimicrobial resistance and common misconceptions surrounding this topic . De Boer  then outlines the future of infectious disease management, highlighting the crucial role of healthcare professionals, policy makers, and the general public in combatting the ‘slow pandemic’. 

Use the following timestamps to navigate the topics in this episode:

(00:00)-Introduction
(00:42)-Antimicrobial stewardship to combat the rise of resistant infections
(05:06)-Main findings from de Boer’s study on antibiotic prescriptions in primary care
(08:57)-Research in evolving epidemiology of antimicrobial resistance
(11:29)-Common misconceptions made by healthcare professionals and the public
(13:40)-The ‘marathon’ of antimicrobial resistance and perceptions of antibiotics
(15:53)-Future of infectious disease management and antibiotic policy
(19:41)-Three wishes for global healthcare

Article 'Trends in antibiotic selection pressure generated in primary care and their association with sentinel antimicrobial resistance patterns in Europe': https://academic.oup.com/jac/article/78/5/1245/7099685

Article 'The Dutch Working Party on Antibiotic Policy (SWAB) guideline for the approach to suspected antibiotic allergy': https://www.sciencedirect.com/science/article/pii/S1198743X23001787?via%3Dihubhttps://pubmed.ncbi.nlm.nih.gov/37068548/

Survey discussed: https://academic.oup.com/cid/search-results?page=1&q=westgeest&fl_SiteID=5269&SearchSourceType=1&allJournals=1#google_vignette

There’s a number of medical discoveries in the last 100 years that can be both life saving and damaging to our health. None more so than antibiotics!

These drugs are literally life-saving for people facing serious bacterial infections.

But they have also created a health epidemic of gut issues, not to mention the frightening rise of antibiotic resistant bacteria - superbugs!

In this episode I share tips for healing your gut after taking a course of antibiotics (and how to hopefully limit your need for them in the future!)

If you read the recent Washington Post article on the subject, you might wonder "should you avoid probiotics if you're taking antibiotics?"

Today I'm going to explain why that isn't the case, by pitting the data from the Washington Post article against the larger body of data that supports the use of probiotics during a course of antibiotics. 

Tune in and be sure to tell me what you think! 

The Study From the Article: 

• https://pubmed.ncbi.nlm.nih.gov/30193113/ 

Counterpoint Studies:

• https://pubmed.ncbi.nlm.nih.gov/36382780/

• https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862129/ 

Continue Learning

• Courses, free guides, and more: https://drruscio.com/resources?utm_source=youtube&utm_medium=link&utm_campaign=drruscio.com_resources

Timestamps

00:00 Intro 

01:11 The article’s claim 

02:13 The one small study he cited

03:13 What most of the data says

05:01 Evidence hierarchy 

07:00 A note about prebiotics

07:44 Healthy people & probiotics

09:20 Be cautious with health news

Get the Latest Updates

Facebook - https://www.facebook.com/DrRusciodc

Instagram - https://www.instagram.com/drrusciodc

Pinterest - https://www.pinterest.ca/drmichaelrusciodc

DISCLAIMER: The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified healthcare provider before starting any new treatment or discontinuing an existing treatment.

Music featured in this video: "Modern Technology" by Andrew G, https://audiojungle.net/user/andrew_g 

*Full transcript available on YouTube by clicking the “Show transcript” button on the bottom right of the video.

Podcast summary of articles from the February 2023 edition of the Journal of Emergency Medicine from the American Academy of Emergency Medicine.  Topics include CT scans in intoxicated patients, pediatric marijuana overdoses, pernicious anemia, antibiotic side effects, heat stroke, and interstitial lung disease.  Guest speaker is Dr. Steffen Simerlink.

One June 11, 2023, over-the-counter sales of specific medically important livestock antibiotics in the United States will end. What does that mean for livestock and companion animal owners, and what will be important to know moving forward into this year? In this episode, podcast team member Kenny Coogan talks with three doctors to help break down the change and how to establish a veterinarian-client-patient relationship.

To see more podcasts, visit our Mother Earth News and Friends page.
Check out the MOTHER EARTH NEWS Bookstore for more resources to help you achieve your health and farming goals.
Go to the MOTHER EARTH NEWS FAIR page for webinar and courses on everything from gardening to livestock management. 

In this episode, we bring you the Evidence on Group B Strep in Pregnancy, in anticipation of the research update to the Signature Article on Group B Strep in Pregnancy.
 
This is Part 1 of a 2-part series. In today’s Part 1, we’ll be talking about:

1. The evidence on GBS during pregnancy
2. The evidence on testing for GBS
3. The evidence on antibiotics, including the pros and cons of giving antibiotics during labor for GBS.

Content Warning: GBS-related stillbirth, infant death, critical illness of newborns, antibiotics, disparities, access to health care.

References and Resources: 

• For a full list of scientific references, see the blog post that goes along with this episode here.
• Find the CDC GBS Prevention App for Obstetric Providers here 
• Find the ACOG GBS Prevention Guidelines here 
• Listen EBB 87: Cristen Pascucci on How to Disagree on Birth Topics Respectfully! here
• Go to our YouTube channel to see video versions of the episode listed above!!
• For more information and news about Evidence Based Birth®, visit www.ebbirth.com.

Find us on: 

• TikTok
• Instagram
• Pinterest

Ready to get involved? 

• Check out our Professional membership (including scholarship options) here 
• Find an EBB Instructor here 
• Click here to learn more about the Evidence Based Birth® Childbirth Class

TWiM explores the relationship between the gut microbiome and depressive symptoms, and how purine nucleotides act as adjuvants to antibiotics.

Hosts: Vincent Racaniello, Michael Schmidt, and Michele Swanson

Subscribe to TWiM (free) on Apple Podcasts, Google Podcasts, Stitcher, Android, RSS, or by email.

Become a Patron of TWiM!

Links for this episode:

• Gut microbiota and depressive symptoms one and two (Nat Commun )
• Microbiome influences depression (Phys.org)
• Gut bacteria and depression (Med Press)
• Mice behaving badly (TWiM 131)
• Gut microbiome in ASD (Front Cell Inf Micro)
• Transferring the blues (J Psych Res)
• Nucleotides as adjuvants to antibiotics (mBio)

Music used on TWiM is composed and performed by Ronald Jenkees and used with permission.

Send your microbiology questions and comments to twim@microbe.tv

NSF's Engineering Research Center for Precision Microbiome Engineering will be creating microbiome technologies that address challenges at the interface of human health and the built environment. We are joined by principal investigator Claudia Gunsch, co-PI Joseph Graves, Duke University Dean of Engineering Jerome Lynch, as well as NSF Director Sethuraman Panchanathan, Assistant Director for Engineering Susan Margulies and ERC Program Director Randy Duran.

This podcast, Dr. Abby Elliott returns and the debut of Dr. Natalie Stoltman, both primary care physicians with Lakeview Clinic. They are both here for the third episode of Ridgeview Podcast CME Series: Journal Review. This is the episode where our speakers talk through new, practice changing and/or just interesting journal articles. In this episode we have six articles addressing subjects related to primary care, including antibiotic prescribing, weight loss modalities, intermittent fasting, non-alcoholic fatty liver disease, LDL levels in relation to coronary plaque, and proton pump inhibitors. The articles referenced in this podcast are linked in the attached show notes.

Enjoy the podcast.

Objectives:
Upon completion of this podcast, participants should be able to:

• Identify when antibotics are warranted for pediatric infections.
• Compare the differences in weight change between individuals who participated in a commercial weight management program to those who participated in a "do-it-yourself (DIY)" approach.
• Explain intermittent fasting and its correlation to health outcomes.
• Define nonalcoholic fatty liver disease and explain the different treatment modalities.
• Explain the correlation between LDL levels and calcium scores/CTA and cardiac outcomes.
• Describe the best practice approach to proton-pump inhibitors (PPI) de-prescribing in ambulatory patients.
• Name significant/relevant findings of the journal articles being reviewed and discussed.

This activity has been planned and implemented in accordance with the accreditation criteria, standards and policies of the Minnesota Medical Association (MMA). Ridgeview is accredited by the Minnesota Medical Association (MMA) to provide continuing medical education for physicians. 

CME credit is only offered to Ridgeview Providers & Allied Health staff for this podcast activity. After listening to the podcast, complete and submit the online evaluation form. Upon successful completion of the evaluation, you will be e-mailed a certificate of completion within approximately 2 weeks. You may contact the accredited provider with questions regarding this program at Education@ridgeviewmedical.org.

Click the link below, to complete the activity's evaluation.

CME Evaluation

(**If you are listening to the podcasts through iTunes on your laptop or desktop, it is not possible to link directly with the CME Evaluation for unclear reasons. We are trying to remedy this. You can, however, link to the survey through the Podcasts app on your Apple and other smart devices, as well as through Spotify, Stitcher and other podcast directory apps and on your computer browser at these websites. We apologize for the inconvenience.) 

DISCLOSURE ANNOUNCEMENT 

The information provided through this and all Ridgeview podcasts as well as any and all accompanying files, images, videos and documents is/are for CME/CE and other institutional learning and communication purposes only and is/are not meant to substitute for the independent medical judgment of a physician, healthcare provider or other healthcare personnel relative to diagnostic and treatment options of a specific patient's medical condition; and are property/rights of Ridgeview Medical Center & Clinics.  Any re-reproduction of any of the materials presented would be infringement of copyright laws. 

It is Ridgeview's intent that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts. It is not assumed any potential conflicts will have an adverse impact on these presentations. It remains for the audience to determine whether the speaker’s outside interest may reflect a possible bias, either the exposition or the conclusions presented.

Ridgeview's CME planning committee members and presenter(s) have disclosed they have no significant financial relationship with a pharmaceutical company and have disclosed that no conflict of interest exists with the presentation/educational event.

Thank-you for listening to the podcast.

SHOW NOTES: 
*See the attachment for article discussion summaries. 

Journal Article 1: "Association of Inappropriate Outpatient Pediatric Antibiotic Prescriptions with Adverse DRug Events and Health Care Expenditures"

CITATION:  Butler AM, Brown DS, Durkin MJ, et al. Association of Inappropriate Outpatient Pediatric Antibiotic Prescriptions With Adverse Drug Events and Health Care Expenditures [published correction appears in JAMA Netw Open. 2022 Jun 1;5(6):e2221479]. JAMA Netw Open. 2022;5(5):e2214153. Published 2022 May 2. doi:10.1001/jamanetworkopen.2022.14153.  Available: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2792723

Journal Article 2: "Efficacy of a Commercial Weight Management Program Compared With a Do-It-Yourself Approach: A Randomized Clinical Trial"

CITATION:  Tate DF, Lutes LD, Bryant M, et al. Efficacy of a Commercial Weight Management Program Compared With a Do-It-Yourself Approach: A Randomized Clinical Trial [published correction appears in JAMA Netw Open. 2022 Sep 1;5(9):e2235316]. JAMA Netw Open. 2022;5(8):e2226561. Published 2022 Aug 1. doi:10.1001/jamanetworkopen.2022.26561  Available: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2795182

Journal Article 3: "Intermittent Fasting and Obesity-Related Health Outcomes: An Umbrella Review of Meta-analyses of Randomized Clinical Trials"

CITATION:  Patikorn C, Roubal K, Veettil SK, et al. Intermittent Fasting and Obesity-Related Health Outcomes: An Umbrella Review of Meta-analyses of Randomized Clinical Trials. JAMA Netw Open. 2021;4(12):e2139558. Published 2021 Dec 1. doi:10.1001/jamanetworkopen.2021.39558.  Available: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2787246

Journal Article 4: "Clinical Care Pathway for the Risk Stratification and Management of Patiemts with Nonalcholic Fatty Liver Disease"

CITATION:  Kanwal F, Shubrook JH, Adams LA, et al. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2021;161(5):1657-1669. doi:10.1053/j.gastro.2021.07.049.  Available: https://www.gastrojournal.org/article/S0016-5085(21)03384-9/fulltext?referrer=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F

Journal Article 5: "Association of Coronary Plaque With Low-Density Lipoprotein Cholesterol Levels and Rates of Cardiovascular Disease Events Among Symptomatic Adults"

CITATION:  Mortensen MB, Caínzos-Achirica M, Steffensen FH, et al. Association of Coronary Plaque With Low-Density Lipoprotein Cholesterol Levels and Rates of Cardiovascular Disease Events Among Symptomatic Adults. JAMA Netw Open. 2022;5(2):e2148139. Published 2022 Feb 1. doi:10.1001/jamanetworkopen.2021.48139.  Available: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2788975

Journal Article 6: "AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review"

CITATION:  Targownik LE, Fisher DA, Saini SD. AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review. Gastroenterology. 2022;162(4):1334-1342. doi:10.1053/j.gastro.2021.12.247.  Available: https://www.gastrojournal.org/article/S0016-5085(21)04083-X/fulltext?referrer=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F

Please check out the additonal show notes for additional information/resources.

What is antimicrobial resistance and how is it impacting us and our health?

For more information checkout: Discovery and preclinical development of new antibiotics (PMID: 24646092), Five barriers to addressing antimicrobial resistance (Author: Rohan Kocharekar), CDC: Antibiotic Rsistance Threats in the United States 2019, National Strategy for Combating Antibioticresistant Bacteria (Obama Administration), National Action Plan for Combating Antibiotic-Resistant Bacteria 2020-2025 (ASPE), United States National Actiona Plan (CDC), Enhancing US-Japan Cooperation to Combat Antimicrobial Resistance (PMID: 25470465), A View on 20 Years of Antimicrobial Resistance in Japan by Two National Surveillance Systems: The National Epidemiological Surveillance of Infectious Diseases and Japan Nosocomial Infections Surveillance (PMID: 34680770), Estimating the Economic and Clinical Value of Reducing Antimicrobial Resistance to Three Gram-negative Pathogens in Japan (PMID: 34703834), Strategy on Antiobiotic Resistance Switzerland (StAR), Epidemiological aspects of non-human antibiotic usage and resistance: implications for the control of antibiotic resistance in Ghana (PMID: 22413809), Occurrence of Antibiotics and Antibiotic-Resistant Bacteria in Landfill Sites in Kumasi, Ghana (Article ID: 6934507), Determinants of Inappropriate Antibiotics Use in Rural Central Ghana Using a Mixed Methods Approach (PMID: 32266200), Resistance to antimicrobial drugs in Ghana (PMID: 22259250), Scoping Report on Antimicrobial Resistance in India, India's National Action Plan for antimicrobial resistance – An overview of the context, status, and way ahead (PMID: 31334140), Antimicrobial resistance in the environment: The Indian scenario (PMID: 31219076).